Identification of a Novel CSNK2A1-PDGFRB Fusion Gene in a Patient with Myeloid Neoplasm with Eosinophilia.

Abstract

Platelet-derived growth factor receptor beta (PDGFRB) rearrangements play an important role in the pathogenesis of eosinophilia-associated myeloid/lymphoid neoplasms. Up to now, more than 70 PDGFRB fusions have been identified. Here, a novel PDGFRB fusion gene CSNK2A1-PDGFRB has been identified in myeloproliferative neoplasm (MPN) with eosinophilia by RNA-sequencing, which has been verified by reverse transcription polymerase chain reaction and Sanger sequencing. The new PDGFRB fusion partner gene CSNK2A1 encoded one of the two catalytic subunit of casein kinase II (CK2). To our knowledge, this is the first report on the involvement of CSNK2A1 in fusion genes, especially fusion with another kinase PDGFRB in MPN. In addition, the CSNK2A1-PDGFRB fusion retained the entire kinase domain of PDGFRB and response to imatinib at low concentration. The patient with CSNK2A1-PDGFRB was sensitive to imatinib treatment and acquired sustained complete remission.

• Authors: Xiaoyu Xu, Qiongyu Lu, Zheng Wang, Ping Cai, Zhao Zeng, Ling Zhang, Man Wang, Liang Ma, Changgeng Ruan, Suning Chen
• Journal: Cancer research and treatment (Cancer Res Treat) Vol. 53 Issue 3 Pg. 889-892 (Jul 2021) ISSN: 2005-9256 [Electronic] Korea (South)
• PMID: 33421986 (Publication Type: Case Reports, Journal Article)

Chemical References

• Oncogene Proteins, Fusion
• Imatinib Mesylate
• PDGFRB protein, human
• Receptor, Platelet-Derived Growth Factor beta
• CSNK2A1 protein, human
• Casein Kinase II

Topics

• Adult
• Biopsy
• Bone Marrow (pathology)
• Casein Kinase II (genetics)
• Eosinophilia (blood, diagnosis, drug therapy, genetics)
• Gene Rearrangement
• Humans
• Imatinib Mesylate (therapeutic use)
• Male
• Myeloproliferative Disorders (blood, diagnosis, drug therapy, genetics)
• Oncogene Proteins, Fusion (genetics)
• Receptor, Platelet-Derived Growth Factor beta (genetics)
• Treatment Outcome